These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38762271)

  • 1. Immunotherapy guided precision medicine in solid tumors.
    Mehrotra S; Kupani M; Kaur J; Kaur J; Pandey RK
    Adv Protein Chem Struct Biol; 2024; 140():249-292. PubMed ID: 38762271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
    Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
    Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanoimmunology in the solid tumor microenvironment.
    Golo M; Newman PLH; Kempe D; Biro M
    Biochem Soc Trans; 2024 Jun; 52(3):1489-1502. PubMed ID: 38856041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes.
    Li T; Sun S; Li Y; Zhang Y; Wei L
    Front Immunol; 2024; 15():1418580. PubMed ID: 39136027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Interplay between T Cells and Cancer: The Basis of Immunotherapy.
    Chen C; Liu X; Chang CY; Wang HY; Wang RF
    Genes (Basel); 2023 Apr; 14(5):. PubMed ID: 37239368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
    Mempel TR; Krappmann D
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organoids: new frontiers in tumor immune microenvironment research.
    Yang Y; Cui J; Kong Y; Hou Y; Ma C
    Front Immunol; 2024; 15():1422031. PubMed ID: 39136020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity.
    Mansouri S; Heylmann D; Stiewe T; Kracht M; Savai R
    Elife; 2022 Sep; 11():. PubMed ID: 36074553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenomics in personalized cancer treatments.
    Kiyotani K; Toyoshima Y; Nakamura Y
    J Hum Genet; 2021 Sep; 66(9):901-907. PubMed ID: 34193979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.
    Bagaev A; Kotlov N; Nomie K; Svekolkin V; Gafurov A; Isaeva O; Osokin N; Kozlov I; Frenkel F; Gancharova O; Almog N; Tsiper M; Ataullakhanov R; Fowler N
    Cancer Cell; 2021 Jun; 39(6):845-865.e7. PubMed ID: 34019806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turning Cold into Hot: Firing up the Tumor Microenvironment.
    Duan Q; Zhang H; Zheng J; Zhang L
    Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine.
    Kumagai S; Itahashi K; Nishikawa H
    Nat Rev Clin Oncol; 2024 May; 21(5):337-353. PubMed ID: 38424196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
    Du Y; Qi Y; Jin Z; Tian J
    Cancer Lett; 2019 Dec; 466():13-22. PubMed ID: 31499119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.
    Liu D
    J Hematol Oncol; 2019 Nov; 12(1):113. PubMed ID: 31703740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold.
    Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT
    Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.